Skip to main content
MTEX
NASDAQ Life Sciences

Mannatech Reports Q1 Profit & Positive Cash Flow Amidst Delisting Threat, Extends Insider Debt

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
9
Price
$4.62
Mkt Cap
$8.915M
52W Low
$4.278
52W High
$12.454
Market data snapshot near publication time

summarizeSummary

Mannatech reported a significant Q1 2026 financial turnaround with a net profit and positive operating cash flow, despite declining sales, as it works to address a Nasdaq delisting threat and 'going concern' warning through cost cuts and debt extensions.


check_boxKey Events

  • Swing to Profitability

    The company reported a net income of $1.0 million ($0.49 EPS) for Q1 2026, a significant improvement from a net loss of $1.5 million ($0.80 loss per share) in Q1 2025.

  • Positive Operating Cash Flow

    Net cash provided by operating activities was $1.1 million in Q1 2026, a substantial turnaround from $1.4 million cash used in Q1 2025. Cash and cash equivalents increased to $7.0 million from $6.2 million at year-end 2025.

  • Continued Sales Decline

    Net sales decreased by 6.2% to $24.9 million in Q1 2026 from $26.6 million in Q1 2025, indicating ongoing revenue challenges.

  • Ongoing Nasdaq Delisting Threat & Negative Equity

    Shareholders' equity remains negative at ($5.554 million) as of March 31, 2026, worsening slightly from ($5.223 million) at December 31, 2025. The company reiterated its 'going concern' warning and acknowledged the Nasdaq delisting notice received on April 20, 2026, for failing to meet minimum stockholders' equity requirements.


auto_awesomeAnalysis

Mannatech's Q1 2026 results show a significant operational turnaround, posting a net income of $1.0 million and positive cash flow from operations of $1.1 million, a stark improvement from a $1.5 million net loss and negative cash flow in Q1 2025. This positive shift is critical as the company faces a Nasdaq delisting notice due to negative shareholders' equity and has an ongoing 'going concern' warning. While net sales declined by 6.2%, management's aggressive cost-cutting measures, including converting director compensation to equity and headcount reductions, along with the extension of $2.75 million in related-party debt, are crucial steps to improve liquidity and address the company's distressed financial state. The ability to generate profit and cash flow is a strong signal of progress in navigating its severe challenges.

At the time of this filing, MTEX was trading at $4.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $4.28 to $12.45. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed MTEX - Latest Insights

MTEX
May 14, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
9
MTEX
May 14, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
9
MTEX
May 14, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
MTEX
Apr 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
MTEX
Apr 24, 2026, 11:55 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
MTEX
Apr 21, 2026, 1:29 PM EDT
Filing Type: DEF 14A
Importance Score:
9
MTEX
Apr 15, 2026, 5:15 PM EDT
Source: Wiseek News
Importance Score:
9
MTEX
Apr 15, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
9
MTEX
Apr 15, 2026, 5:08 PM EDT
Filing Type: 10-K
Importance Score:
10
MTEX
Apr 01, 2026, 6:47 PM EDT
Filing Type: 8-K
Importance Score:
9